## Cristoforo Comi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5680219/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guillain–BarrÃ <sup>~</sup> syndrome following COVID-19 vaccine mRNA-1273: a case report. Acta Neurologica Belgica, 2022, 122, 1369-1371.	1.1	10
2	Susac Syndrome: an uncommon cause of impaired vision. Neurological Sciences, 2022, 43, 3919-3922.	1.9	2
3	Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis. Journal of Neurology, 2022, 269, 3249-3257.	3.6	20
4	Oxidative Stress in Non-Alcoholic Fatty Liver Disease. Livers, 2022, 2, 30-76.	1.9	21
5	The Immune System as a Therapeutic Target for Old and New Drugs in Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2022, 21, .	1.4	1
6	Immune Response Modifications in the Genetic Forms of Parkinson's Disease: What Do We Know?. International Journal of Molecular Sciences, 2022, 23, 3476.	4.1	5
7	The Role of Tau beyond Alzheimer's Disease: A Narrative Review. Biomedicines, 2022, 10, 760.	3.2	12
8	Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. The Lancet Digital Health, 2022, 4, e359-e369.	12.3	19
9	T Lymphocytes in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, S65-S74.	2.8	17
10	Striatal dopamine transporter imaging in Parkinson's disease drug-naÃ⁻ve patients: focus on sexual dysfunction. Neurological Sciences, 2022, 43, 4769-4776.	1.9	6
11	The Effects of COVID-19-Related Restrictions on Parkinson's Disease Patients in Italy: Results of a Structured Survey. Journal of Clinical Medicine, 2022, 11, 3007.	2.4	3
12	Early Successful Eye Movement Desensitization and Reprocessing (EMDR) Therapy for Verbal Memory Impairment in an Adjustment Disorder: A Case Report in a Newly-Diagnosed Multiple Sclerosis Patient. Reports, 2022, 5, 17.	0.5	1
13	<scp>CD4</scp> + <scp>Tâ€cell</scp> Transcription Factors in Idiopathic <scp>REM</scp> Sleep Behavior Disorder and Parkinson's Disease. Movement Disorders, 2021, 36, 225-229.	3.9	25
14	Kinematic but not clinical measures predict falls in Parkinson-related orthostatic hypotension. Journal of Neurology, 2021, 268, 1006-1015.	3.6	5
15	Expanding the genetic spectrum of primary familial brain calcification due to SLC2OA2 mutations: a case series. Neurogenetics, 2021, 22, 65-70.	1.4	4
16	Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study. Neural Regeneration Research, 2021, 16, 2475.	3.0	6
17	Paraneoplastic neuromyelitis optica spectrum disorders: a case series. Neurological Sciences, 2021, 42, 2519-2522.	1.9	7
18	The Yin-Yang of osteopontin in nervous system diseases: damage versus repair. Neural Regeneration Research, 2021, 16, 1131.	3.0	29

#	Article	IF	CITATIONS
19	Telehealth in Neurodegenerative Diseases: Opportunities and Challenges for Patients and Physicians. Brain Sciences, 2021, 11, 237.	2.3	34
20	The Impact of the COVID-19 Pandemic on the Cognition of People with Dementia. International Journal of Environmental Research and Public Health, 2021, 18, 4285.	2.6	29
21	Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 507-514.	2.8	15
22	Polymorphisms of Dopamine Receptor Genes and Parkinson's Disease: Clinical Relevance and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 3781.	4.1	17
23	Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19. Disease Markers, 2021, 2021, 1-7.	1.3	24
24	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	9.0	26
25	The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson's Disease. Life, 2021, 11, 804.	2.4	10
26	Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103231.	2.0	13
27	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 159-167.	2.9	8
28	Neuromyelitis optica with syringomyelia: A case report and neurosonological follow up. Journal of the Neurological Sciences, 2021, 429, 118287.	0.6	0
29	A challenging diagnosis of neurodegenerative dementia: Psychiatric onset of frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2021, 429, 119008.	0.6	0
30	CSF Tau protein correlates with cognitive impairment in multiple sclerosis patients at diagnosis. Journal of the Neurological Sciences, 2021, 429, 117752.	0.6	0
31	An Investigation of the Role of Common and Rare Variants in a Large Italian Multiplex Family of Multiple Sclerosis Patients. Genes, 2021, 12, 1607.	2.4	4
32	The impact of COVID-19 pandemic on cognition of people with dementia. Journal of the Neurological Sciences, 2021, 429, 117797.	0.6	0
33	Why searching for Anti-Contactin-1 antibodies in chronic inflammatory demyelinating polyneuropathy: a case report Neuroimmunology Reports, 2021, 1, 100034.	0.4	0
34	Increased Prevalence of Neuropsychiatric Disorders during COVID-19 Pandemic in People Needing a Non-Deferrable Neurological Evaluation. Journal of Clinical Medicine, 2021, 10, 5169.	2.4	5
35	Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patients. Brain Sciences, 2021, 11, 1521.	2.3	14
36	Motor and non-motor symptom improvement after mRNA-1273 vaccine in a Parkinson's disease patient. Neurological Sciences, 2021, , 1.	1.9	2

#	Article	IF	CITATIONS
37	Contribution of Rare and Low-Frequency Variants to Multiple Sclerosis Susceptibility in the Italian Continental Population. Frontiers in Genetics, 2021, 12, 800262.	2.3	3
38	Beta2-Adrenoceptor Agonists in Parkinson's Disease and Other Synucleinopathies. Journal of NeuroImmune Pharmacology, 2020, 15, 74-81.	4.1	22
39	Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson's disease. Brain, Behavior, and Immunity, 2020, 89, 668-674.	4.1	39
40	Intrathecal kappa free light chains as markers for multiple sclerosis. Scientific Reports, 2020, 10, 20329.	3.3	29
41	Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. Scientific Reports, 2020, 10, 20731.	3.3	96
42	Change over time of COVID-19 hospital presentation in Northern Italy. European Journal of Internal Medicine, 2020, 81, 100-103.	2.2	7
43	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. Journal of Neural Transmission, 2020, 127, 881-891.	2.8	8
44	Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiologie Clinique, 2020, 50, 47-54.	2.2	13
45	Cortical visuomotor interactions in Freezing of Gait: A TMS approach. Neurophysiologie Clinique, 2020, 50, 205-212.	2.2	3
46	The vermiform appendix in Parkinson's disease: At the crossroad of peripheral immunity, the nervous system and the intestinal microbiome. Autoimmunity Reviews, 2019, 18, 102357.	5.8	6
47	TAM Receptor Pathways at the Crossroads of Neuroinflammation and Neurodegeneration. Disease Markers, 2019, 2019, 1-13.	1.3	46
48	Exploiting PLGA-Based Biocompatible Nanoparticles for Next-Generation Tolerogenic Vaccines against Autoimmune Disease. International Journal of Molecular Sciences, 2019, 20, 204.	4.1	86
49	Post-lumbar puncture headache: an adverse effect in multiple sclerosis work-up. Neurological Sciences, 2019, 40, 759-762.	1.9	2
50	Ultrasonography Monitoring of Optic Nerve Sheath Diameter and Retinal Vessels in Patients with Cerebral Hemorrhage. Journal of Neuroimaging, 2019, 29, 394-399.	2.0	20
51	K Index is a Reliable Marker of Intrathecal Synthesis, and an Alternative to IgG Index in Multiple Sclerosis Diagnostic Work-Up. Journal of Clinical Medicine, 2019, 8, 446.	2.4	27
52	Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence. Frontiers in Immunology, 2019, 10, 969.	4.8	83
53	Holmes tremor caused by a natalizumab-related progressive multifocal leukoencephalopathy: a case report and brief review of the literature. Neurological Sciences, 2019, 40, 1943-1945.	1.9	3
54	Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis. Cells, 2019, 8. 262.	4.1	9

#	Article	IF	CITATIONS
55	Kappa free light chains could predict early disease course in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 30, 81-84.	2.0	23
56	FRI0258â€ANTI-RO/SSA POSITIVITY, ANTI-AQUAPORIN4 ANTIBODIES AND CENTRAL NERVOUS SYSTEM INVOLVEMENT: A RETROSPECTIVE STUDY ON A CONTROVERSIAL CORRELATION. , 2019, , .		0
57	Editorial: Peripheral Immunity in Parkinson's Disease: Emerging Role and Novel Target for Therapeutics. Frontiers in Neurology, 2019, 10, 1080.	2.4	6
58	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	1.9	59
59	Vogt-Koyanagi-Harada Syndrome: A Case of Bilateral Steroid-Responsive Loss of Vision. , 2019, 1, .		0
60	MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis. Multiple Sclerosis and Related Disorders, 2018, 21, 9-10.	2.0	13
61	Real life evaluation of safinamide effectiveness in Parkinson's disease. Neurological Sciences, 2018, 39, 733-739.	1.9	22
62	Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. Frontiers in Neurology, 2018, 9, 1001.	2.4	61
63	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
64	LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients. Journal of Neuroimmunology, 2018, 324, 129-135.	2.3	37
65	Chronic obstructive pulmonary disease may complicate Alzheimer's disease: a comorbidity problem. Neurological Sciences, 2018, 39, 1585-1589.	1.9	18
66	Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naÃ⁻ve and drug-treated patients. Journal of Neuroinflammation, 2018, 15, 205.	7.2	174
67	The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson's Disease. Frontiers in Neurology, 2018, 9, 213.	2.4	21
68	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2018, 17, 597-608.	10.2	101
69	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
70	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Scientific Reports, 2017, 7, 43718.	3.3	35
71	<scp>P</scp> revalence and burden of dysautonomia in advanced Parkinson's disease. Movement Disorders, 2017, 32, 796-797.	3.9	18
72	A patient with autoimmune limb-girdle myasthenia, and a brief review of this treatable condition Clinical Neurology and Neurosurgery, 2017, 158, 53-55.	1.4	1

#	Article	IF	CITATIONS
73	The measuring of substantia nigra hyperechogenicity in an Italian cohort of Parkinson disease patients: a case/control study (NOBIS Study). Journal of Neural Transmission, 2017, 124, 869-879.	2.8	6
74	Peripheral neuropathy as marker of severe Parkinson's disease phenotype. Movement Disorders, 2017, 32, 1256-1258.	3.9	22
75	Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia. British Journal of Haematology, 2017, 176, 258-267.	2.5	8
76	Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis. Journal of Neuroimaging, 2017, 27, 92-96.	2.0	8
77	Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson's Disease. International Journal of Molecular Sciences, 2017, 18, 242.	4.1	43
78	Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2017, 8, 321.	4.8	30
79	Longitudinal Assessment of Transorbital Sonography, Visual Acuity, and Biomarkers for Inflammation and Axonal Injury in Optic Neuritis. Disease Markers, 2017, 2017, 1-5.	1.3	11
80	Insights into the protective role of immunity in neurodegenerative disease. Neural Regeneration Research, 2017, 12, 64.	3.0	30
81	Combined use of Kappa Free Light Chain Index and Isoelectrofocusing of Cerebro-Spinal Fluid in Diagnosing Multiple Sclerosis: Performances and Costs. Clinical Laboratory, 2017, 63, 551-559.	0.5	31
82	MRI imaging and clinical features of sciatic nerve injection injury. International Journal of Neuroscience, 2016, 126, 1-2.	1.6	3
83	Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells <i>In Vitro</i> and Mouse Experimental Autoimmune Encephalomyelitis <i>In Vivo</i> . Journal of Immunology Research, 2016, 2016, 1-13.	2.2	40
84	Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. Journal of Immunology Research, 2016, 2016, 1-15.	2.2	120
85	Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 59-65.	2.6	41
86	Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease. Scientific Reports, 2016, 6, 33738.	3.3	91
87	Polymorphisms of dopamine receptor genes are associated to increased risk of visual hallucinations in Italian Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 22, e170.	2.2	0
88	Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients. European Journal of Clinical Pharmacology, 2016, 72, 1335-1341.	1.9	19
89	<i>D</i> <scp><i>NAJC</i></scp> <i>6</i> <scp>M</scp> utations <scp>A</scp> ssociated <scp>W</scp> ith <scp>E</scp> arlyâ€ <scp>O</scp> nset <scp>P</scp> arkinson's <scp>D</scp> isease. Annals of Neurology, 2016, 79, 244-256.	5.3	148
90	Impaired visual inhibition in migraine with aura. Clinical Neurophysiology, 2015, 126, 1988-1993.	1.5	15

6

#	Article	IF	CITATIONS
91	Variations of the perforin gene in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Genes and Immunity, 2015, 16, 99-102.	4.1	9
92	Intensive Rehabilitation Treatment in Early Parkinson's Disease. Neurorehabilitation and Neural Repair, 2015, 29, 123-131.	2.9	137
93	Predicting Cognitive Decline in Parkinsonââ,¬â,,¢s Disease: Can We Ask the Genes?. Frontiers in Neurology, 2014, 5, 224.	2.4	11
94	Revisiting the Molecular Mechanism of Neurological Manifestations in Antiphospholipid Syndrome: Beyond Vascular Damage. Journal of Immunology Research, 2014, 2014, 1-9.	2.2	35
95	Transorbital Sonography in Acute Optic Neuritis: A Case-Control Study. American Journal of Neuroradiology, 2014, 35, 2371-2375.	2.4	38
96	Current Understanding on the Role of Standard and Immunoproteasomes in Inflammatory/Immunological Pathways of Multiple Sclerosis. Autoimmune Diseases, 2014, 2014, 1-12.	0.6	27
97	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: From Molecular Bases to Practical Considerations. Autoimmune Diseases, 2014, 2014, 1-11.	0.6	20
98	Advances in Neuroimmunology: From Bench to Bedside. Autoimmune Diseases, 2014, 2014, 1-2.	0.6	0
99	Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism and Related Disorders, 2014, 20, 27-31.	2.2	73
100	Intensive Rehabilitation Increases BDNF Serum Levels in Parkinsonian Patients. Neurorehabilitation and Neural Repair, 2014, 28, 163-168.	2.9	118
101	Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies. Parkinsonism and Related Disorders, 2014, 20, 1329-1334.	2.2	64
102	Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis. Vaccine, 2014, 32, 5681-5689.	3.8	116
103	Defining the Epsilonâ€Sarcoglycan (SGCE) Gene Phenotypic Signature in Myoclonusâ€Dystonia: A Reappraisal of Genetic Testing Criteria. Movement Disorders, 2013, 28, 787-794.	3.9	31
104	Evidence of Pre-Synaptic Dopaminergic Deficit in a Patient with a Novel Progranulin Mutation Presenting with Atypical Parkinsonismâ€. Journal of Alzheimer's Disease, 2013, 38, 747-752.	2.6	19
105	Variations of the UNC13D Gene in Patients with Autoimmune Lymphoproliferative Syndrome. PLoS ONE, 2013, 8, e68045.	2.5	20
106	Immunity and inflammation in neurodegenerative diseases. American Journal of Neurodegenerative Disease, 2013, 2, 89-107.	0.1	83
107	Robotic Gait Training Is not Superior to Conventional Treadmill Training in Parkinson Disease. Neurorehabilitation and Neural Repair, 2012, 26, 1027-1034.	2.9	56
108	The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression. Clinical and Developmental Immunology, 2012, 2012, 1-6.	3.3	31

#	Article	IF	CITATIONS
109	Rehabilitation improves dyskinesias in Parkinsonian patients: A pilot study comparing two different rehabilitative treatments. NeuroRehabilitation, 2012, 30, 295-301.	1.3	16
110	Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease. Scientific Reports, 2012, 2, 953.	3.3	38
111	The role of T cell apoptosis in nervous system autoimmunity. Autoimmunity Reviews, 2012, 12, 150-156.	5.8	40
112	The -346T polymorphism of the SH2D1A gene is a risk factor for development of autoimmunity/lymphoproliferation in males with defective Fas function. Human Immunology, 2012, 73, 585-592.	2.4	9
113	Effectiveness of Intensive Inpatient Rehabilitation Treatment on Disease Progression in Parkinsonian Patients. Neurorehabilitation and Neural Repair, 2012, 26, 144-150.	2.9	90
114	Dopaminergic therapies modulate the T ELL proteome of patients with Parkinson's disease. IUBMB Life, 2012, 64, 846-852.	3.4	43
115	Anti-cytokine autoantibodies in autoimmune diseases. American Journal of Clinical and Experimental Immunology, 2012, 1, 136-46.	0.2	25
116	Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 306-308.	1.9	106
117	GSK3β genetic variability in patients with Multiple Sclerosis. Neuroscience Letters, 2011, 497, 46-48.	2.1	20
118	Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neuroscience Letters, 2011, 504, 9-12.	2.1	147
119	Complex pattern of convulsive syncope in glossopharyngeal neuralgia: Video/EEG report and short review. Epilepsy and Behavior, 2011, 20, 407-409.	1.7	20
120	Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. BMJ Case Reports, 2011, 2011, bcr1120103549-bcr1120103549.	0.5	14
121	The Role of Osteopontin in Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2011, 25, 179-185.	2.6	81
122	Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers. Journal of Alzheimer's Disease, 2011, 27, 781-790.	2.6	45
123	Fasâ€mediated Tâ€cell apoptosis in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2011, 16, 45-47.	3.1	9
124	Signals of Apoptotic Pathways in Several Types of Meningioma. Pathology and Oncology Research, 2011, 17, 51-59.	1.9	5
125	Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline. Journal of Alzheimer's Disease, 2010, 19, 1143-1148.	2.6	100
126	Levodopaâ€induced belly dancer's dyskinesias in Parkinson's disease: Report of one case. Movement Disorders, 2010, 25, 1760-1762.	3.9	18

#	Article	IF	CITATIONS
127	A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 2010, 17, 289-294.	3.3	115
128	Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. Genes and Immunity, 2010, 11, 497-503.	4.1	17
129	Defective Fasâ€mediated Tâ€cell apoptosis predicts acute onset CIDP. Journal of the Peripheral Nervous System, 2009, 14, 101-106.	3.1	24
130	FP17-TU-06 Th17, an effector T lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon (IFN)-β. Journal of the Neurological Sciences, 2009, 285, S84.	0.6	0
131	Complex movement disorders in primary antiphospholipid syndrome: A case report. Journal of the Neurological Sciences, 2009, 281, 101-103.	0.6	16
132	Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. Journal of the Neurological Sciences, 2009, 287, 291-293.	0.6	83
133	Variations of the perforin gene in patients with multiple sclerosis. Genes and Immunity, 2008, 9, 438-444.	4.1	39
134	Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis. Journal of the Neurological Sciences, 2008, 267, 86-90.	0.6	30
135	MDC/CCL22 intrathecal levels in patients with multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 547-549.	3.0	28
136	Spontaneous Intracranial Hypotension Presenting as a Reversible Dorsal Midbrain Syndrome. Journal of Neuro-Ophthalmology, 2008, 28, 289-292.	0.8	15
137	Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis. Neuroscience Letters, 2007, 425, 173-176.	2.1	6
138	CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. European Journal of Neurology, 2007, 14, 162-167.	3.3	19
139	ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. Journal of Neuroimmunology, 2007, 186, 193-198.	2.3	24
140	Fas-mediated T-cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2006, 11, 53-60.	3.1	17
141	ICOS cooperates with CD28, IL-2, and IFN-γ and modulates activation of human naìve CD4+ T cells. European Journal of Immunology, 2006, 36, 2601-2612.	2.9	38
142	Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. Journal of Neuroimmunology, 2005, 163, 172-178.	2.3	66
143	E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis. Journal of Neuroimmunology, 2005, 165, 201-205.	2.3	17
144	P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis. Neuroscience Letters, 2005, 388, 149-152.	2.1	13

#	Article	IF	CITATIONS
145	Cutaneous silent period in human immunodeficiency virus-related peripheral neuropathy. Journal of the Peripheral Nervous System, 2004, 9, 224-231.	3.1	16
146	Abnormal response to glutamate of T lymphocytes from multiple sclerosis patients. Neuroscience Letters, 2003, 340, 5-8.	2.1	13
147	Diagnosis of psychogenic paralysis: The role of motor evoked potentials. Journal of Neurology, 2001, 248, 889-897.	3.6	39
148	Defective T cell Fas function in patients with multiple sclerosis. Neurology, 2000, 55, 921-927.	1.1	100
149	Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood, 2000, 95, 3176-3182.	1.4	2